1. Home
  2. PBYI vs LCW Comparison

PBYI vs LCW Comparison

Compare PBYI & LCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • LCW
  • Stock Information
  • Founded
  • PBYI 2010
  • LCW 2021
  • Country
  • PBYI United States
  • LCW United States
  • Employees
  • PBYI N/A
  • LCW N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • LCW Blank Checks
  • Sector
  • PBYI Health Care
  • LCW Finance
  • Exchange
  • PBYI Nasdaq
  • LCW Nasdaq
  • Market Cap
  • PBYI 176.1M
  • LCW 165.8M
  • IPO Year
  • PBYI N/A
  • LCW 2021
  • Fundamental
  • Price
  • PBYI $2.39
  • LCW $10.99
  • Analyst Decision
  • PBYI Strong Buy
  • LCW
  • Analyst Count
  • PBYI 1
  • LCW 0
  • Target Price
  • PBYI $7.00
  • LCW N/A
  • AVG Volume (30 Days)
  • PBYI 392.8K
  • LCW 41.8K
  • Earning Date
  • PBYI 10-31-2024
  • LCW 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • LCW N/A
  • EPS Growth
  • PBYI N/A
  • LCW N/A
  • EPS
  • PBYI 0.18
  • LCW N/A
  • Revenue
  • PBYI $219,143,000.00
  • LCW N/A
  • Revenue This Year
  • PBYI N/A
  • LCW N/A
  • Revenue Next Year
  • PBYI N/A
  • LCW N/A
  • P/E Ratio
  • PBYI $12.77
  • LCW N/A
  • Revenue Growth
  • PBYI N/A
  • LCW N/A
  • 52 Week Low
  • PBYI $2.13
  • LCW $10.59
  • 52 Week High
  • PBYI $7.73
  • LCW $11.03
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 37.64
  • LCW 54.11
  • Support Level
  • PBYI $2.23
  • LCW $11.00
  • Resistance Level
  • PBYI $2.42
  • LCW $11.01
  • Average True Range (ATR)
  • PBYI 0.17
  • LCW 0.01
  • MACD
  • PBYI 0.00
  • LCW -0.00
  • Stochastic Oscillator
  • PBYI 27.59
  • LCW 61.25

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About LCW Learn CW Investment Corporation

Learn CW Investment Corp is a blank check company. It is formed for the purpose of effecting a merger, consolidation, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: